CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients

Pharmacogenomics

Volumn 15, Issue 2, 2014, Pages 179-188

  Kurzawski, Mateusz ^a   Da̧browska, Justyna ^a   Dziewanowski, Krzysztof ^b   Domański, Leszek ^a   Peruzyńska, Magdalena ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Marie Curie Regional Hospital   (Poland)

Author keywords

CYP3A4; CYP3A5; kidney transplantation; pharmacogenetics; tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ADULT; ALLELE; ARTICLE; BODY WEIGHT; CAUCASIAN; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DOSE RESPONSE; DRUG CONCENTRATION; DRUG DOSE REDUCTION; FEMALE; GENE EXPRESSION; GENE LOCUS; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLAND; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; IMMUNOSUPPRESSIVE TREATMENT; PROCEDURES;

CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84893062040     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.199     Document Type: Article

References (37)

1. Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. Am. J. Health Syst. Pharm. 69(22), 1961-1975 (2012).
2. Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther. Drug Monit. 31(2), 139-152 (2009).
3. Shiraga T, Matsuda H, Nagase K et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47(4), 727-735 (1994).
4. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis. Pharmacogenet. Genomics 22(8), 642-645 (2012).
5. Adler G, Loniewska B, Parczewski M, Kordek A, Ciechanowicz A. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol. Rep. 61(5), 947-951 (2009).
6. Hashimoto H, Toide K, Kitamura R et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218(2), 585-595 (1993).
7. Birdwell K A, Grady B, Choi L et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22(1), 32-42 (2012).
8. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
9. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
10. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
11. Li Y, Hu X, Cai B et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transplant. Immunol. 27(1), 12-18 (2012).
12. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
13. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
14. Balbontin FG, Kiberd B, Squires J et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant. Proc. 35(7), 2445-2448 (2003).
15. Scholten EM, Cremers SC, Schoemaker RC et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 67(6), 2440-2447 (2005).
16. Rebbeck TR, Troxel AB, Wang Y et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst. 98(18), 1311-1320 (2006).
17. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011).
18. Kurzawski M, Drozdzik M. Pharmacogenetics in solid organ transplantation: Genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics 14(9), 1099-1118 (2013).
19. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the 'missing heritability' problem. Front. Genet. 4, 12 (2013).
20. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90(16), 1225-1229 (1998).
21. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42(4), 299-305 (2003).
22. Hesselink DA, van Schaik RHN, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
23. Tavira B, Coto E, Diaz-Corte C, Alvarez V, Lopez-Larrea C, Ortega F. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenet. Genomics 23(8), 445-448 (2013).
24. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transplant. Int. 25(4), 471-480 (2012).
25. Roy JN, Barama A, Poirier C, Vinet B, Roger M. CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16(9), 659-665 (2006).
26. Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Suarez-Kurtz G. CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin. Pharmacol. Ther. 94(2), 201-202 (2013).
27. Gijsen VM, van Schaik RH, Elens L et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 14(9), 1027-1036 (2013).
28. Sadee W, Wang D, Papp AC et al. Pharmacogenomics of the RNA world: Structural RNA polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89(3), 355-365 (2011).
29. Klein K, Thomas M, Winter S et al. PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6), 1044-1052 (2012).
30. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit. 32(4), 394-404 (2010).
31. Tavira B, Garcia EC, Diaz-Corte C et al. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49(5), 825-833 (2011).
32. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
33. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
34. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948-957 (2011).
35. Passey C, Birnbaum AK, Brundage RC et al. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 13(10), 1141-1147 (2012).
36. Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IA. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br. J. Clin. Pharmacol. 76(3), 425-431 (2013).
37. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br. J. Clin. Pharmacol. 75(6), 1545-1547 (2013).